Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Woodcock's Consideration of Sarepta Financial Issues Raises Eyebrows

Executive Summary

CDER Director tells FDA appeals board that Duchenne muscular dystrophy development could suffer if Sarepta's drug not approved.

Advertisement

Related Content

Woodcock's 'Bias' In Sarepta Case Made Jenkins Worry About Future Drug Reviews
Exondys Approval: Measured Efficacy Outcomes Vs. Patient 'Anecdotes'
Sarepta’s Aftermath: FDA Staff Still Working Together, Califf Says
Sarepta Pressured FDA On Eteplirsen Due To ‘Dire’ Finances, Gave Investors Rosier Picture
Political Appointees Shouldn't Influence Approval Decisions, Califf Says
Sarepta's Shadow: BioMarin Mulls Turning The Extraordinary Into A Template
Sarepta's Eteplirsen Approved After Contentious Internal FDA Debate
Patients Can't Rescue Sarepta's Eteplirsen
BioMarin's Drisapersen 'Compete Response' Shows FDA Flexibility Still Limited
FDA Orphan Approval Flexibility Remains Steady As Pressure Increases

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS119158

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel